Effects of statins on endothelium and signaling mechanisms

Stroke

Volumn 35, Issue 11 SUPPL. 1, 2004, Pages 2708-2711

  Endres, Matthias ^a,c   Laufs, Ulrich ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute care

Indexed keywords

ACTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; NITRATE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAC PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; STATIN; SUPEROXIDE;

ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG WITHDRAWAL; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME; UP-REGULATION;

EID: 7644242146     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000143319.73503.38     Document Type: Conference Paper

References (22)

1. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20(Suppl 2):II-11-II-7.
2. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease and other high-risk conditions. Lancet. 2004;363:757-767.
3. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30:1969-1973.
4. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelium function within one month. Circulation. 1997;95:1126-1131.
5. Gorlach A, Brandes RP, Nguyen K, Amidi M, Deghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26-32.
6. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPAse. Mol Pharmacol. 2001;59:646-654.
7. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
8. Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
9. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
10. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
11. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Leer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
12. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
13. Laufs U, Endres M, Stagliano NE, Amin-Hanjani S, Chui D-S, Yang S-X, Simoncini T, Yamada M, Rabkin E, Allen PG, Huang PL, Böhm M, Schoen FJ, Moskowitz MA, Liao JK. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000;106:15-24.
14. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
15. Gertz K, Laufs U, Lindauer U, Nickenig G, Böhm M, Dirnagl U, Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
16. Pucetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A, Crcignani M, Palazzuoli A, Auteri A, Bruni F. Platelet hyperactivity after statin treatment discontinuation. Thromb Haemost. 2003;90:476-482.
17. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res. 202;91:173-179.
18. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998;352:1830-1831.
19. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD; for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
20. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Withdrawal of statins in patients with acute coronary syndromes. Circulation. 2003;107:e27.
21. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Böhm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastastin in healthy, normocholesterolemic men. Am J Cardiol. 2001;88:1306-1307.
22. Spencer FA, Fonarow GC, Frederick P, Wright RS, Every N, Dong W, Goldberg RJ, Lambrew C, French WJ. Does early withdrawal of statin therapy in patients with acute coronary syndromes increase hospital morbidity and mortality? Circulation 2002;106(suppl II):493. Abstract 2435.